A major concern is the net operating loss for the quarter that surged to $11.8 million inclusive of $1.7 million in stock based compensation charges. This was nearly double an operating loss of $6.6 million that had been reported for the first three months of 2013. Galena Biopharma Inc. (NASDAQ:GALE) also incurred expense due to non-cash charges that amounted to $9.8 million up from $5 million reported last year. Net loss, on the other hand, dropped to $2.5 million compared to a net loss of $9.3 million a year earlier.

Buying more at 2.48 today

$GALE | Galena Biopharma, is down 50% since we reported $1,031,000 of insider selling on 01/31/2014. Did you protect your investment?

Make no mistake about it; Galena's future looks as if it'll live and die by the hands of NeuVax, so that's what shareholders should really be watching

NEW ORLEANS, LA--(Marketwired - May 1, 2014) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 5, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galena Biopharma, Inc. (NASDAQ: GALE). Investor losses must relate to purchases of the Company's securities during the extended period of May 9, 2013 and March 17, 2014, inclusive. This action is pending in the United States District Court for the District of Oregon.

What You May Do

If you purchased shares of Galena and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com) or KSF Partner Melinda Nicholson (melinda.nicholson@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by May 5, 2014.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. (“Galena” or the “Company”) (GALE) securities between November 6, 2013 and February 14, 2014.

For more information, click here: zlk.9nl.com/galenabiopharma-gale.

The complaint alleges that throughout the Class Period, Galena made false and/or misleading statements that led to the artificial inflation of Galena’s stock price, allowing its Chief Executive Officer to sell $3.8 million worth of his Galena stock.

On February 12, 2014, an article featured on TheStreet.com alleged Galena was engaging in a misleading campaign aimed at boosting its stock price, alleging that investor relations firm The DreamTeam Group had published articles under aliases promoting the Company’s stock without disclosing their sponsorship. Then on February 14, 2014, Galena acknowledged that it had paid the investor relations firm The DreamTeam Group to promote the Company.

If you suffered a loss in Galena you have until May 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/galenabiopharma-gale.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 27, 2014

Notice is hereby given to the holders of common stock of Galena Biopharma, Inc., that the Annual Meeting of Stockholders will be held on Friday, June 27, 2014, at the Nines Hotel, 6 th Floor, 525 SW Morrison, Portland, Oregon 97204 at 9:00 A.M., local time, for the following purposes:



(1) To elect three directors to serve until the 2017 annual meeting of stockholders;



(2) To approve, by non-binding vote, the compensation of our named executive officers as disclosed in this proxy statement;



(3) To ratify the selection of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014; and



(4) To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.